![Incyte](https://www.adcreviews.com/wp-content/uploads/2022/10/Incyte-238x160.jpg)
Incyte acquires Villaris Therapeutics for $1.43 billion
On October 3, Incyte announced the acquisition of Villaris Therapeutics, which was invested and incubated by Medicxi, and acquired the latter’s anti-IL-15Rβ monoclonal antibody drug
On October 3, Incyte announced the acquisition of Villaris Therapeutics, which was invested and incubated by Medicxi, and acquired the latter’s anti-IL-15Rβ monoclonal antibody drug